Bristol Myers reports positive Phase 3 data on iza-bren
Question
Bristol Myers reports positive Phase 3 data on iza-bren
Direct answer
Positive late-stage oncology data can re-rate BMY pipeline value and influence oncology peer multiples through asset-specific trial probability.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-27
- Published
- 2026-10-27
- Revision
- 1 · 2026-10-28
Cite as: Market Ontology, “Bristol Myers reports positive Phase 3 data on iza-bren”, revision 1, evidence through 2026-10-27. https://marketontology.com/market-events/2026-10-27/bristol-myers-reports-positive-phase-3-data-on-iza-bren-a939e3
How this development reaches the affected companies
| Asset | Exposure and channel | Direction | Evidence |
|---|---|---|---|
| BMY | positive Phase 3 oncology data supports pipeline valuation | Up1-4w | The Motley Fool says Bristol Myers Squibb announced positive Phase 3 trial results and progression-free survival was 11.1 months versus 5.7 months. |
| JNJ | oncology trial read-through can influence peer valuation multiples | Mixed1-4w | The article includes JNJ in the ticker set. |
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| JNJ | Mixed | 266.30 2026-10-26 | Pending | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related
- 2026-10-27Bristol Myers Squibb lung cancer candidate doubles progression-free survivalBMY
- 2026-10-27Bristol Myers Squibb lung cancer candidate doubles progression-free survivalBMY XBI
- 2026-10-27Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLCBMY
- 2026-10-27Bristol Myers reported positive Phase 3 data for iza-brenBMY
- 2026-10-27Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLCBMY
- 2026-10-27Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLCBMY
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.